These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37816422)

  • 1. Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies.
    Hollister J; Caban-Martinez AJ; Ellingson KD; Beitel S; Fowlkes AL; Lutrick K; Tyner HL; Naleway AL; Yoon SK; Gaglani M; Hunt D; Meece J; Mayo Lamberte J; Schaefer Solle N; Rose S; Dunnigan K; Khan SM; Kuntz JL; Fisher JM; Coleman A; Britton A; Thiese MS; Hegmann KT; Pavuk M; Ramadan FA; Fuller S; Nematollahi A; Sprissler R; Burgess JL
    Environ Res; 2023 Dec; 239(Pt 1):117297. PubMed ID: 37816422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response to SARS-CoV-2 mRNA vaccination in Danish adults exposed to perfluoroalkyl substances (PFASs): The ENFORCE study.
    Timmermann A; Johansen IS; Tolstrup M; Heilmann C; Budtz-Jørgensen E; Tolstrup JS; Nielsen F; Grandjean P
    Environ Res; 2024 Dec; 263(Pt 1):120039. PubMed ID: 39326653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.
    Constantin AM; Noertjojo K; Sommer I; Pizarro AB; Persad E; Durao S; Nussbaumer-Streit B; McElvenny DM; Rhodes S; Martin C; Sampson O; Jørgensen KJ; Bruschettini M
    Cochrane Database Syst Rev; 2024 Apr; 4(4):CD015112. PubMed ID: 38597249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of per- and polyfluoroalkyl substances and heavy metals with blood lipid profiles in a representative sample of Korean adolescents.
    Kim Y; Shin S; Choe Y; Cho J; Kim C; Kim SH; Kim KN
    Environ Health; 2024 Nov; 23(1):104. PubMed ID: 39578875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The T cell response to SARS-CoV-2 mRNA vaccine in adults with high exposure to perfluoroalkyl substances from Ronneby, Sweden.
    Andersson AG; Lundgren A; Xu Y; Nielsen C; Lindh CH; Pineda D; Vallin J; Johnsson C; Fletcher T; Bemark M; Jakobsson K; Li Y
    Chemosphere; 2024 Dec; 369():143770. PubMed ID: 39566685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal exposure to PFAS and the association with neurobehavioral and social development during childhood.
    Saha T; Gbemavo MCJ; Booij L; Arbuckle TE; Ashley-Martin J; Fisher M; Muckle G; Lanphear B; Asztalos E; Séguin J; Bouchard MF
    Int J Hyg Environ Health; 2025 Jan; 263():114469. PubMed ID: 39326240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
    PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
    Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF
    BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early pregnancy serum PFAS are associated with alterations in the maternal lipidome.
    Rabotnick MH; Haidari A; Dolinoy DC; Meijer JL; Harris SM; Burant CF; Padmanabhan V; Goodrich JM
    Environ Res; 2024 Dec; 263(Pt 3):120183. PubMed ID: 39426451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Per- and polyfluoroalkyl substances, apolipoproteins and the risk of coronary heart disease in US men and women.
    Zhu L; Liu B; Hu Y; Wang M; Furtado JD; Rimm EB; Grandjean P; Sun Q
    Environ Health; 2024 Dec; 23(1):108. PubMed ID: 39627728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure to perfluoroalkyl and polyfluoroalkyl substances and risk of stroke in adults: a meta-analysis.
    Chang MC; Chung SM; Kwak SG
    Rev Environ Health; 2024 Dec; 39(4):791-800. PubMed ID: 37656598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum per- and polyfluoroalkyl substance (PFAS) levels and health-related biomarkers in a pilot study of skiers in New England.
    Claus Henn B; Leonard ER; Doherty BT; Byrne S; Hartmann N; Ptolemy AS; Ayanian S; Crawford KA
    Environ Res; 2024 Dec; 263(Pt 2):120122. PubMed ID: 39389198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Kennedy NA; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Liu Z; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Goodhand JR; Hart AL; Lees CW; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):342-352. PubMed ID: 35123676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PFAS and menopause onset: Is it just a matter of reverse causation? Cross-sectional and longitudinal analyses in highly exposed women in the Veneto Region.
    Berti M; Cavicchio L; Rosato I; Fletcher T; Pitter G; Russo F; Batzella E; Canova C
    Environ Res; 2025 Jan; 264(Pt 1):120305. PubMed ID: 39510233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding prenatal household exposures to per- and polyfluorylalkyl substances using paired Biological and dust measurements with sociodemographic and housing variables.
    Wallis DJ; Miller KE; DeLuca NM; Thomas K; Fuller C; McCord J; Cohen Hubal EA; Minucci JM
    Environ Int; 2024 Dec; 194():109157. PubMed ID: 39642652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Per- and poly-fluoroalkyl substances (PFAS) accelerate biological aging mediated by increased C-reactive protein.
    Zhao Z; Zhou J; Shi A; Wang J; Li H; Yin X; Gao J; Wu Y; Li J; Sun YX; Yan H; Li Y; Chen G
    J Hazard Mater; 2024 Dec; 480():136090. PubMed ID: 39405719
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.